Intrinsiqq
OnKure Therapeutics Inc. logo

OnKure Therapeutics Inc. Insider Trading

OKUR

Compare
Last 12 months

Insiders sold 6K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in May 2023.

Net open-market
−6K
0 buys · 8 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
0 / 2
executives and directors
Last open-market buy
May 2023
May 8, 2023

Get an email when OKUR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 21No plan
    Jason A. Leverone
    Chief Financial Officer · sold 302 at $2.97
    $897
    1.6% of stake
  • Sep 21No plan
    Nicholas A Saccomano
    President and CEO · sold 87 at $2.97
    $258
    0.8% of stake
  • Jun 22No plan
    Jason A. Leverone
    Chief Financial Officer · sold 303 at $4.40
    1K
    1.6% of stake
  • Jun 22No plan
    Nicholas A Saccomano
    President and CEO · sold 86 at $4.40
    $378
    0.8% of stake
  • Mar 23No plan
    Jason A. Leverone
    Chief Financial Officer · sold 301 at $4.16
    1K
    1.8% of stake
  • Mar 23No plan
    Nicholas A Saccomano
    President and CEO · sold 86 at $4.16
    $358
    1.2% of stake
  • Dec 22, 2025No plan
    Jason A. Leverone
    Chief Financial Officer · sold 302 at $2.97
    $897
    1.8% of stake
  • Dec 22, 2025No plan
    Nicholas A Saccomano
    President and CEO · sold 87 at $2.97
    $258
    1.2% of stake
  • Sep 22, 2025No plan
    Jason A. Leverone
    Chief Financial Officer · sold 303 at $2.62
    $794
    2.3% of stake
  • Sep 22, 2025No plan
    Nicholas A Saccomano
    President and CEO · sold 88 at $2.62
    $231
    2.4% of stake
  • Jun 23, 2025No plan
    Nicholas A Saccomano
    President and CEO · sold 88 at $2.38
    $209
    2.4% of stake
  • Jun 23, 2025No plan
    Jason A. Leverone
    Chief Financial Officer · sold 303 at $2.38
    $721
    2.3% of stake
  • May 15, 2025
    Acorn Capital Advisors GP, LLC
    Large holder · bought 1,400,000 at avg $1.85
    $2.59M
    97% of stake
  • May 15, 2025No plan
    Cormorant Private Healthcare Fund III LP
    Large holder · sold 1,813,439 at $1.85
    $3.35M
    100% of stake
  • May 12, 2025No plan
    Cormorant Global Healthcare Master Fund, LP
    Large holder · sold 24,300 at $1.99
    48K
    1.3% of stake
  • Apr 4, 2025 – Apr 7, 2025No plan
    Nicholas A Saccomano
    President and CEO · sold 874 at avg $2.94
    3K
    19% of stake
  • Apr 4, 2025 – Apr 7, 2025No plan
    Jason A. Leverone
    Chief Financial Officer · sold 3,122 at avg $2.94
    9K
    19% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch OKUR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with OKUR

CompareIntrinsic value
HRMYHarmony Biosciences Holdings, Inc.
$32.59-1.18%80
DNTHDianthus Therapeutics Inc.
$84.55-0.33%10
PGENPrecigen Inc.
$4.21+1.20%29
DSGNDesign Therapeutics, Inc.
$9.02-3.22%10
SMMTSummit Therapeutics Inc.
$10.46-1.09%10
MDGLMadrigal Pharmaceuticals, Inc.
$379.10-4.45%10
ARDXArdelyx Inc.
$2.99-2.29%40
AQSTAquestive Therapeutics Inc.
$3.46-6.61%10

Held by ETFs

OKUR is in 2 US ETFs. The largest of them, with OKUR's weight in each:

Spot a number that looks wrong? Check it in OKUR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing OKUR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.